The earnings call highlighted significant improvements in gross margin and reductions in operating expenses, driven by a successful strategic shift and a focus on routine users. However, these positive developments are counterbalanced by a notable decrease in revenue and flowcell sales, and challenges related to global trade uncertainties.

Company Guidance -

Q2 2025

During the Bionano First Quarter 2025 Earnings Conference Call, the company provided detailed guidance on its strategic shift and financial metrics. Bionano reported a Q1 2025 total revenue of $6.5 million, marking a 26% decrease from Q1 2024, influenced by the cessation of clinical services. The installed base of OGM systems grew by 9% year-over-year, with nine new installations in Q1, bringing the total to 379 systems. Despite a 15% decline in flowcell sales, excluding new customer sales, there was a 1% increase in flowcells sold to existing customers compared to the previous year. The GAAP and non-GAAP gross margins improved significantly to 46%, up from 32% and 34% respectively, in Q1 2024, driven by cost savings initiatives and supply chain optimizations. Operating expenses saw a substantial reduction, down to $11.4 million on a GAAP basis and $8.5 million on a non-GAAP basis. Bionano's cash and equivalents stood at $29.2 million, with a cash runway extending into Q1 2026, aided by a $10 million registered direct offering and ATM sales. The company expects full-year revenues to range between $26 million and $30 million, with Q2 revenues anticipated between $6.3 million and $6.8 million, and plans to install 15 to 20 new OGM systems in 2025.

Significant Improvement in Gross Margin

GAAP and non-GAAP gross margin for the first quarter of 2025 was 46%, significantly higher than the 32% GAAP and 34% non-GAAP gross margin reported for the first quarter of 2024.

Substantial Decrease in Operating Expenses

First quarter 2025 GAAP operating expense was $11.4 million, a 66% decrease compared to $33.9 million in the first quarter of 2024. Non-GAAP operating expense was $8.5 million, compared to $24.4 million in the prior year.

Increase in Installed Base of OGM Systems

The installed base of OGM systems grew to 379, which is a 9% year-over-year increase.

Successful Strategic Shift

The company executed a strategic shift focusing on existing users with the potential to be routine users of Bionano's products.

Strong Academic and Clinical Publications

The first quarter of 2025 had 95 publications, second only to the 99 publications in the first quarter of 2024. Notably, MD Anderson Cancer Center published a study highlighting the utility of optical genome mapping.

BioNano Genomics (BNGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BNGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 14, 2025	2025 (Q2)	-2.63 / -	-14.4	―	―	―
May 14, 2025	2025 (Q1)	- / -	-36	―	―
Mar 31, 2025	2024 (Q4)	-3.02 / -1.15	-36	96.80% (+34.85)	―
Nov 13, 2024	2024 (Q3)	-11.85 / -31.20	-193.2	83.85% (+162.00)	―
Aug 07, 2024	2024 (Q2)	-24.92 / -14.40	-74.4	80.65% (+60.00)	―
May 08, 2024	2024 (Q1)	-38.65 / -36.00	-72	50.00% (+36.00)	―
Mar 05, 2024	2023 (Q4)	-52.24 / -66.90	-78	14.23% (+11.10)	―
Nov 08, 2023	2023 (Q3)	-58.18 / -193.20	-66	-192.73% (-127.20)	―
Aug 09, 2023	2023 (Q2)	-62.55 / -74.40	-66	-12.73% (-8.40)	―
May 09, 2023	2023 (Q1)	-62.72 / -72.00	-66	-9.09% (-6.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BNGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$3.74	$3.93	+5.08%
Mar 31, 2025	$2.79	$3.10	+11.11%
Nov 13, 2024	$16.61	$15.35	-7.59%
Aug 07, 2024	$25.90	$24.16	-6.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioNano Genomics Inc (BNGO) report earnings?

BioNano Genomics Inc (BNGO) is schdueled to report earning on Aug 14, 2025, After Close (Confirmed).

What is BioNano Genomics Inc (BNGO) earnings time?

BioNano Genomics Inc (BNGO) earnings time is at Aug 14, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BNGO EPS forecast?

BNGO EPS forecast for the fiscal quarter 2025 (Q2) is -2.63.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing